A

AUPH

AUPH

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
36%Bearish
Buy/Sell Ratio90% buys
BearishBullish
AUPH Live QuoteReal-time
$14.70
$2.63(-15.18%)1M
Day Range$14.63 – $14.97
Open$14.69
Previous Close$14.89
Volume1.34M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$2.01B
P/E Ratio (TTM)6.6
Forward P/E11.1
EPS (TTM)$2.28
Price to Book3.1
Dividend Yield0.65%
Beta (Volatility)1.34
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $14.70 (21%)
Low: $13.52High: $19.25
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$18.50-87.7% upside

Insider Buys

5

$62.27M

Insider Sales

9

$6.70M

Total Volume

$68.97M

14 transactions

Net Activity

+$55.57M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
95CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Strong buying bias: purchases represent 90% of total transaction value.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
T
1

Tang Kevin

CEO, 10%

5 buys0 sells

$62.27M total

G
2

Greenleaf Peter

CEO

0 buys1 sells

$2.87M total

R
3

Robertson Stephen P.

GC

0 buys3 sells

$1.52M total

D
4

Donley Matthew Maxwell

COO

0 buys1 sells

$994K total

M
5

Miller Joseph M

CFO

0 buys1 sells

$940K total

Trading History
AUPH insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 10, 2026

2 months ago

Robertson Stephen P.

GC

General Counsel
Sell11.9K$15.95$190K

Aug 21, 2026

3 months ago

Robertson Stephen P.

GC

General Counsel
Sell21.0K$16.97$356K

May 29, 2026

5 months ago

Tang Kevin

CEO, 10%

CEO
Buy814.6K$15.29$12.46M

Feb 27, 2026

8 months ago

Tang Kevin

Dir

Director
Buy900.0K$14.10$12.69M

Aug 1, 2025

15 months ago

Tang Kevin

Dir

Director
Buy1.30M$10.45$13.59M

Aug 1, 2025

15 months ago

Keenan Greg

Chief Medical Officer

C-Level
Sell20.0K$10.50$210K

Mar 7, 2025

20 months ago

Keenan Greg

Chief Medical Officer

C-Level
Sell8.3K$8.23$68K

Mar 3, 2025

20 months ago

Greenleaf Peter

CEO

CEO
Sell360.5K$7.96$2.87M

Mar 3, 2025

20 months ago

Keenan Greg

Chief Medical Officer

C-Level
Sell12.2K$8.00$98K

Mar 3, 2025

20 months ago

Miller Joseph M

CFO

CFO
Sell118.0K$7.96$940K

Mar 3, 2025

20 months ago

Robertson Stephen P.

EVP, GC

EVP
Sell122.5K$7.96$975K

Mar 3, 2025

20 months ago

Donley Matthew Maxwell

COO

COO
Sell124.9K$7.96$994K

Feb 28, 2025

21 months ago

Tang Kevin

Dir

Director
Buy1.60M$7.95$12.71M

Dec 5, 2024

23 months ago

Tang Kevin

Dir

Director
Buy1.20M$9.02$10.82M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
AUPH Buy Conviction90%
Industry Rank#0 of 569
Volume Contribution0.4%
Total Industry Activity$16.52B

AUPH has an insider buy conviction of 90%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for AUPH

Over the last 90 days, corporate insiders at AUPH (AUPH) engaged in a total of 14 transactions reported via SEC Form 4 filings. Among these, 5 were open-market purchases and 9 were sales. The total volume of insider trading reached $68.97M.

The net insider activity for AUPH shows a net buying bias of $55.57M. This activity represents a 90% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Tang Kevin (Dir), who traded 1.30M shares valued at $13.59M on Aug 1, 2025.

Live Market News & Developments
Aggregated real-time headlines for AUPH (AUPH)
6 updates

Aurinia Pharmaceuticals Stock Price Forecast. Should You Buy AUPH?

StockInvest.us4d ago

Aurinia Pharmaceuticals (NASDAQ:AUPH) in Focus: Unusual Volume and the Latest Quarterly Report

kalkine.ca1h ago

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Yahoo Finance84d ago

AUPH - Aurinia Pharmaceuticals Inc Stock Price and Quote

Finviz178d ago

Aurinia Pharmaceuticals (AUPH) Stock Price Slips After Q3 Earnings Strength

Simply Wall St19d ago

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

The Motley Fool166d ago

FAQs About AUPH Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for AUPH.

Based on SEC Form 4 disclosures, the Insider Confidence Score for AUPH is currently 95/100, which reflects a strong accumulation bias. This calculation accounts for a total of 5 purchases and 9 sales by company executives over the last 90 days.

The CEO Conviction Index for AUPH is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.